Velocity Clinical Research

12/15/2025

We’re thrilled to announce that four Velocity physicians have officially become Board-Certified in Obesity Medicine—a tremendous achievement at a time when groundbreaking research and treatments are transforming obesity care.
- Fritz Raiser, DO – Omaha, NE
- Daniel Williams, DO – Anderson, SC
- Shishir Khetan, MD – Rockville, MD
- Asefa Mekonnen, MD, FCCP, FAASM – Rockville, MD

With the addition of these four P*s, Velocity now has 20+ Principal Investigators who are either Board-Certified in Obesity Medicine or actively progressing toward certification. This milestone underscores our commitment to advancing evidence-based care for patients navigating obesity—a complex, chronic disease—especially as new studies and therapies continue to reshape the landscape.

Join us in congratulating these outstanding physicians!

12/12/2025

🎄 Day 5 of the 12 Days of Velocity: Collaboration That Sparkles! ✨

This season, we’re celebrating a partnership that’s shaping the future of clinical trials! Velocity is collaborating with Merck to enhance how trial insights are shared across our global network.

Together, we’ve developed the Velocity Insight Platform (VIP)—a dynamic dashboard delivering fast-response data exchange and actionable metrics to optimize site activities.

A huge thank you to the Merck data team for their dedication to this groundbreaking project. Like a string of holiday lights, this collaboration brightens the path toward better trials for participants, Sponsors, and sites worldwide. ❄️

12/11/2025

🎄 Day 4 of the 12 Days of Velocity: Innovation Wrapped in Recognition! ✨

At the SCOPE Summit, Velocity and our VISION platform were honored with the Site Innovation Award—a true celebration of progress and patient access!

VISION is now available in four countries and four languages, with the VISION Engage app downloaded over 100,000 times. To date, it has supported:
🎁 8,700 randomizations
🎁 $5.3M in-app patient stipend payments
🎁 Continuous data refinement on 1.5M patients

This recognition is a testament to our mission: making trials more accessible, efficient, and patient-centered worldwide. Here’s to more innovation in the year ahead! ❄️

12/10/2025

🎄 Day 3 of the 12 Days of Velocity: A Feast of Ideas in Atlanta! 🍽️❄️

While the leaves were falling in November, Velocity gathered leaders from across the clinical research industry for a warm, private dinner during ObesityWeek® in Atlanta.

We were honored to host an off-the-record discussion with Dr. Jerome Adams, the 20th U.S. Surgeon General, alongside executives from IQVIA, AltrixBio, Fortrea, Boehringer Ingelheim, and Roche.

From diversity in trials to the future of patient access, the conversation was candid, insightful, and forward-looking—proof that collaboration is the secret ingredient to progress.

A heartfelt thank you to everyone who joined us for this memorable evening. Here’s to more shared tables and transformative ideas in the year ahead!

11/27/2025

On this day of Thanksgiving, we pause to reflect on the blessings that surround us — family, friends, health, and the joys of life.

At Velocity, we are thankful for the opportunity to contribute to advancements in science and improve lives. We're also grateful for our patients, clients, and partners for your trust and support.

May your day be filled with warmth, laughter, and love. Happy Thanksgiving!

11/20/2025

At ObesityWeek in Atlanta, Stanley Hsia, MD, presented results from a Phase 2 Eli Lilly and Company/Innovent Biologics study of mazdutide, a once-weekly injectable GLP-1/glucagon dual agonist. The study demonstrated dose-dependent weight loss.

Dr. Hsia: "All of these mazdutide treatment curves did not seem to plateau, suggesting that had we continued treatment beyond 48 weeks, greater degrees of weight loss might actually have been seen."

Participants experienced decreased HbA1c, and those on higher-dose regimens (10 and 16 mg) also experienced declines in LDL cholesterol, non-HDL cholesterol, and triglycerides.

Read the full recap from Healio: https://www.healio.com/news/endocrinology/20251118/glp1glucagon-dual-agonist-reduces-weight-across-three-dosing-regimens-in-obesity

11/12/2025

Velocity Clinical Research welcomes Andrew (Drew) Reina as Chief Revenue Officer (CRO).

Drew brings more than two decades of global clinical research experience, having led high-performing commercial teams and strategic partnerships at both Fortrea (formerly Labcorp Drug Development) and PPD, where he oversaw a $1B+ global portfolio of Phase II–IV studies.

“This has been a challenging year for clinical research in many ways,” said Paul Evans, President & CEO of Velocity. “Andrew’s experience at Fortrea brings deep CRO-centric leadership to our team and helps position Velocity not just as an exceptional site network, but as a strategic partner — particularly for biotech and leading pharma companies.”

“Sponsors and CROs increasingly rely on MCRCs to accelerate speed to market and reduce burden on both sites and patients,” added Drew Reina. “Velocity is exceptionally positioned to meet those needs, and I’m energized by the opportunity to contribute to its continued growth and impact.”

As Velocity enters a new phase of consolidation and growth, Drew’s appointment reinforces our mission to deliver high-quality, patient-focused research through a holistic operations and commercial strategy, helping Sponsors and CROs bring new treatments to patients faster, with greater consistency and quality.

Learn more about Drew's appointment and Velocity’s integrated site network: https://velocityclinical.com/velocity-appoints-former-fortrea-executive-andrew-reina-as-chief-revenue-officer

11/11/2025

This Veteran's Day, we pay tribute to the brave men and women who have selflessly served. Your sacrifices and dedication inspire us all.

Join us in saluting our heroes and standing together in appreciation and respect.

10/07/2025

Generative AI is reshaping clinical research—but its true power lies in the data behind it. In his latest op-ed, Tyler Beasley explores how Velocity’s integrated site network and smart infrastructure make our data AI-ready from day one, unlocking real-world impact for patients, Sponsors, and CROs.

Highlights:
- 70+ owned sites across the U.S. & Europe, with LATAM expansion underway
- 3× faster site activation than CROs
- 1.5M+ patient database with 20% outside traditional care centers
- VISION platform: AI-powered tools improving recruitment, retention & equity
- VIP dashboards: Real-time insights for Sponsors

Velocity is building the future of clinical trials—faster, smarter, and more equitable.

Read the full op-ed: https://velocityclinical.com/op-ed-how-data-is-driving-genai-solutions-in-clinical-trials/

10/01/2025

09/18/2025

The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution.

The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean mass loss typically associated with GLP-1 therapy, while enhancing fat loss.

As the lead investigator for the trial, Dr. Rosenstock stated in the Regeneron press release: “These complete 26-week COURAGE results demonstrate a meaningful opportunity to preserve muscle mass while enhancing fat loss.”

Also noted: “Numerical improvements in metabolic and lipid parameters, secondary and exploratory endpoints, were seen across all treatment groups, including improvements in waist circumference, blood pressure, cholesterol, triglycerides and A1C.”

Read the full press release:
https://investor.regeneron.com/news-releases/news-release-details/results-phase-2-courage-trial-demonstrating-potential-improve

08/22/2025

Heading to Orlando for the SCRS Global Site Solutions Summit? Discover how Velocity is accelerating research programs for Sponsors and improving the clinical trial experience for participants.

At this event:
• Paul Evans
• Sara Smiley, DO, FACP
• Craig Koch
• Jenn Carl
• Dan Robitaille
• Paul Kergides
• Grant Miller

Connect with our team before the show and visit us at booth 219!